Biopharmaceutical company PureTech Health plc (LSE: PRTC) reported on Wednesday the appointment of Dr Susan Dillon as an independent member to the board of Vedanta Biosciences.
Vedanta is a clinical-stage company that was founded by PureTech.
Dr Dillon brings extensive drug development experience in immunology and infectious disease, having led the approvals and expansions of several blockbuster products.
She is co-founder, president and CEO of biotechnology company Aro Biotherapeutics and previously served as global therapeutic area head for immunology at Janssen Research & Development LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ). During her 16 years at Janssen, Dr Dillon led biologics discovery and global immunology R&D teams that were responsible for achieving numerous regulatory approvals for innovative antibody products for autoimmune diseases.
Dr Dillon also currently serves on the board of directors of the Wistar Institute and is an advisor to the DMAX Foundation, which focuses on mental health.
4basebio synthetic DNA used in Phase I/II mRNA therapy trial
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
Merck KGaA to acquire JSR Life Sciences chromatography business to expand Protein A capabilities
60 Degrees reports first patient has tested negative for babesiosis in tafenoquine study
INOVIO announces inducement grant to new employee
Hologic receives FDA clearance and CE mark for new gastrointestinal bacterial assays
LakeShore Biopharma receives Nasdaq delisting determination letter
CorMedix to acquire Melinta Therapeutics in USD300m deal to expand infectious disease portfolio
INOVIO to release Q2 2025 financial results on 12 August
Bavarian Nordic chikungunya vaccine enters Health Canada review process
Ondine Biomedical completes world-first ICU study with Steriwave nasal therapy